Fate Therapeutics (FATE) Current Assets (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Current Assets data on file, last reported at $179.5 million in Q1 2026.

• Quarterly Current Assets fell 27.67% year-over-year to $179.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.5 million (down 27.67% YoY) and the FY2025 annual result came in at $208.7 million, down 28.5% from the prior year.
• Current Assets retreated to $179.5 million in Q1 2026, from $208.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $599.2 million in Q2 2022 to a low of $179.5 million in Q1 2026.
• A 5-year average of $362.7 million and a median of $331.5 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets decreased 9.94% — and 2025, when it sank 37.06%.
• Tracing FATE's Current Assets over 5 years: stood at $502.1 million in 2022, then tumbled by 33.97% to $331.5 million in 2023, then slipped by 11.95% to $291.9 million in 2024, then retreated by 28.5% to $208.7 million in 2025, then retreated by 13.98% to $179.5 million in 2026.
• The last three Current Assets figures came in at $179.5 million (Q1 2026), $208.7 million (Q4 2025), and $221.3 million (Q3 2025), per Business Quant data.